Typical Starting Dose for Ramipril
The typical starting dose of ramipril for adult patients with hypertension is 2.5 mg once daily, which can be initiated at 1.25 mg once daily in patients with renal impairment, volume depletion, or those at risk for hypotension. 1
Standard Dosing for Hypertension
- For patients NOT receiving a diuretic: The recommended initial dose is 2.5 mg once daily 1
- The usual maintenance dosage range is 2.5 mg to 20 mg per day, administered as a single dose or in two equally divided doses 2, 1
- If the antihypertensive effect diminishes toward the end of the dosing interval with once-daily dosing, consider increasing the dose or switching to twice-daily administration 1
Modified Starting Doses for Special Populations
Renal Impairment
- For patients with creatinine clearance <40 mL/min: Start with 1.25 mg once daily 1
- Maximum total daily dose should not exceed 5 mg in patients with significant renal impairment 1
Volume Depletion or Renal Artery Stenosis
- If volume depletion is suspected (e.g., from diuretic use) or renal artery stenosis is present: Initiate at 1.25 mg once daily 1
- Adjust dosage according to blood pressure response 1
Heart Failure Post-Myocardial Infarction
- Starting dose: 2.5 mg twice daily (5 mg total per day) 1
- Patients who become hypotensive may be switched to 1.25 mg twice daily 1
- After one week, increase toward a target dose of 5 mg twice daily (if tolerated), with dosage increases spaced approximately 3 weeks apart 1
- Observe patients under medical supervision for at least 2 hours after the initial dose and until blood pressure stabilizes for an additional hour 1
Clinical Context from Guidelines
The 2017 ACC/AHA hypertension guidelines list ramipril with a usual dose range of 2.5–20 mg per day, administered once or twice daily, consistent with the FDA-approved dosing 2. Research studies have demonstrated that ramipril is effective across this dosing spectrum, with efficacy rates of 28.1% at 1.25 mg, 52.2% at 2.5 mg, 69.6% at 5 mg, and 78.3% at 10 mg in patients with mild to moderate hypertension 3.
Important Caveats
- Avoid in pregnancy due to ACE inhibitor teratogenicity 2
- Do not combine with ARBs or direct renin inhibitors 2
- Monitor for hyperkalemia, especially in patients with CKD or those on potassium supplements or potassium-sparing drugs 2
- Risk of acute renal failure in patients with severe bilateral renal artery stenosis 2
- Do not use if history of angioedema with ACE inhibitors 2